Article ; Online: The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute.
Journal of the National Cancer Institute
2020 Volume 113, Issue 11, Page(s) 1453–1459
Abstract: ... from oncology clinical trials at Dana-Farber Cancer Institute from January 1, 2018, to June 30, 2020, including ... blood collections decreased dramatically after Dana-Farber Cancer Institute implemented COVID-19-related ...
| Abstract | Interventions designed to limit the spread of coronavirus disease 2019 (COVID-19) are having profound effects on the delivery of health care, but data showing the impact on oncology clinical trial enrollment, treatment, and monitoring are limited. We prospectively tracked relevant data from oncology clinical trials at Dana-Farber Cancer Institute from January 1, 2018, to June 30, 2020, including the number of open trials, new patient enrollments, in-person and virtual patient visits, dispensed investigational infusions, dispensed or shipped oral investigational agents, research biopsies, and blood samples. We ascertained why patients came off trials and determined on-site clinical research staffing levels. We used 2-sided Wilcoxon rank sum tests to assess the statistical significance of the reported changes. Nearly all patients on interventional treatment trials were maintained, and new enrollments continued at just under one-half the prepandemic rate. The median number of investigational prescriptions shipped to patients increased from 0 to 74 (range = 22-107) per week from March to June 2020. The median number of telemedicine appointments increased from 0 to 107 (range = 33-267) per week from March to June 2020. Research biopsies and blood collections decreased dramatically after Dana-Farber Cancer Institute implemented COVID-19-related policies in March 2020. The number of research nurses and clinical research coordinators on site also decreased after March 2020. Substantial changes were required to safely continue clinical research during the pandemic, yet we observed no increases in serious adverse events or major violations related to drug dosing. Lessons learned from adapting research practices during COVID-19 can inform industry sponsors and governmental agencies to consider altering practices to increase operational efficiency and convenience for patients. |
|---|---|
| MeSH term(s) | COVID-19/epidemiology ; COVID-19/virology ; Clinical Trials as Topic/organization & administration ; Clinical Trials as Topic/statistics & numerical data ; Humans ; Neoplasms/therapy ; Neoplasms/virology ; Research Subjects/psychology ; Research Subjects/statistics & numerical data ; SARS-CoV-2/physiology ; United States/epidemiology |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-09-22 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2992-0 |
| ISSN | 1460-2105 ; 0027-8874 ; 0198-0157 |
| ISSN (online) | 1460-2105 |
| ISSN | 0027-8874 ; 0198-0157 |
| DOI | 10.1093/jnci/djaa144 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.131: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.